DDX3X and disease arising from reactivation of latent virus: In antiviral drug development, DDX3X-specific inhibitors such as RK-33, FH-1321, and the novel compound 6b block DDX3X’s ATPase or RNA-binding domains, demonstrating dual efficacy in suppressing viral replication and reversing latent infection (Rao et al., 2021).